London, 21 March 2023
The European Commission has published an amendment to the Medical Device Regulation (MDR) in the Official Journal. One of the amendment’s main features is the extension of the MDR transition periods until 31 December 2027 or 31 December 2028, depending on the device class.
Regulation (EU) 2023/607 of 15 March 2023, amending Regulations (EU) 2017/745 (MDR) and (EU) 2017/746 (IVDR) as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices, came into force on 20 March 2023. The Regulation introduces an extension of the transition periods provided for in the MDR as long as certain conditions are fulfilled.
It also deletes, in both the MDR and the IVDR, the "sell-off" date, which is the end date after which devices that have already been placed on the market, and remain available for purchase, should be withdrawn.
The Regulation also introduces a new transition period until 26 May 2026 for manufacturers of Class III custom-made implantable devices to obtain certification of their Quality Management System by a Notified Body, as long as certain criteria are met.
“For manufacturers and Authorised Representatives with legacy devices that are eligible under Article 120(2) of the MDR, as amended, their certificates will either have been extended or reactivated automatically on 20 March 2023” explains Haroon Atchia, QFI’s CEO and Technical Director. “However, at this time, there is no mechanism to demonstrate that an expired certificate is still valid, so the Commission will need to provide formal direction and/or guidance on this issue in due course.”
The official press release from the European Commission can be found here:
Quality First International assists medical device manufacturers in becoming compliant with the MDR requirements. Any enquiries or doubts about the new Regulation and its possible consequences may be addressed to: enquiries@qualityfirstint.com.
About Quality First International (QFI)
QFI is a London-based medical devices consulting company specialising in solving its clients’ regulatory, technical and compliance challenges to enable medical devices to enter the global marketplace. QFI provides regulatory advice, quality assurance and clinical trial services, with particular emphasis on the European, US, Japanese, Australian, Canadian, Mexican and Chinese marketplaces. All submissions made by QFI have fulfilled the compliance requirements first time round, consistently. QFI’s clients range from start-up companies to multinational organisations, primarily developing a broad range of cutting edge, minimally invasive and cardiovascular products and implants. QFI also specialises in various remediation and business excellence initiatives including solutions to regulatory enforcement, corporate integrity arrangements and expert witness services.
For further information please contact:
Tel: +44 (0)208 221 2361, Email: enquiries@qualityfirstint.com, Website: www.qualityfirstint.com.
HAVE A QUERY? CONTACT US
Thank you for your enquiry.
One of our team will be in contact soon. If your query is urgent, please contact the office directly via telephone or email and we will be happy to help.
Quality First International
1 Cook’s Road
Stratford
E15 2PW
London
United Kingdom
Tel: +44 (0)208 221 2361
All Rights Reserved | Quality First International